Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences Inc. (TSE:APS)
:APS
APS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.02 - C$17.40
Previous CloseN/A
Volume48.76K
Average Volume (3M)3.70K
Market Cap
C$4.21M
Enterprise ValueC$16.69M
Total Cash (Recent Filing)C$553.00K
Total Debt (Recent Filing)C$11.38M
Price to Earnings (P/E)―
Beta-1.34
Next Earnings
Nov 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.81
Shares Outstanding2,552,429
10 Day Avg. Volume2,716
30 Day Avg. Volume3,698
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$8.22Price Target Upside397.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.
Clinical Trial ProgressAptose has made progress in progressing tuspetinib in the clinic, including initiating and reporting early safety and efficacy data from TUSCANY, a Phase 1/2 triplet combo study in newly diagnosed acute myeloid leukemia.
Financial StabilityThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.
Bears Say
Funding NeedsNegotiating a new tuspetinib co-development collaboration agreement is necessary to provide additional funding and accelerate clinical development.
Aptose Biosciences News
APS FAQ
What was Aptose Biosciences Inc.’s price range in the past 12 months?
Aptose Biosciences Inc. lowest stock price was C$1.02 and its highest was C$17.40 in the past 12 months.
What is Aptose Biosciences Inc.’s market cap?
Aptose Biosciences Inc.’s market cap is C$4.21M.
When is Aptose Biosciences Inc.’s upcoming earnings report date?
Aptose Biosciences Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 59 days.
How were Aptose Biosciences Inc.’s earnings last quarter?
Aptose Biosciences Inc. released its earnings results on Aug 13, 2025. The company reported -C$3.81 earnings per share for the quarter, missing the consensus estimate of -C$3.782 by -C$0.028.
Is Aptose Biosciences Inc. overvalued?
According to Wall Street analysts Aptose Biosciences Inc.’s price is currently Undervalued.
Does Aptose Biosciences Inc. pay dividends?
Aptose Biosciences Inc. does not currently pay dividends.
What is Aptose Biosciences Inc.’s EPS estimate?
Aptose Biosciences Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptose Biosciences Inc. have?
Aptose Biosciences Inc. has 2,552,429 shares outstanding.
What happened to Aptose Biosciences Inc.’s price movement after its last earnings report?
Aptose Biosciences Inc. reported an EPS of -C$3.81 in its last earnings report, missing expectations of -C$3.782. Following the earnings report the stock price went up 4.07%.
Which hedge fund is a major shareholder of Aptose Biosciences Inc.?
Currently, no hedge funds are holding shares in TSE:APS
Company Description
Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Technical Analysis
XORTX Therapeutics Inc
―
Core One Labs
―
―
BioVaxys Technology
―
Rakovina Therapeutics Inc
―
Options Prices
Currently, No data available
---